Arvinas, Inc. (ARVN) Earnings Call Transcript
November 3, 2026
Earnings Call Speaker Segments
Good morning, everyone, and thanks for being with us today. Earlier this morning, we put out a press release covering our financial results for the third quarter of 2026, and you can find it in the Investors and Media section of our website at arvinas.com. With us on today's call are Randy Teel, our President and CEO; Angela Cacace, our Chief Scientific Officer; and Andrew Saik, our Chief Financial Officer. Before we get started, I want to remind you that this discussion includes forward-looking statements, which carry risks, uncertainties and assumptions. Those risks and uncertainties are described in today's press release and in the company's recent filings with the Securities and Exchange Commission, and I encourage you to read them. Actual results could differ materially from what we discuss on today's call. A replay of this call, along with today's press release and an updated corporate deck, will be posted on the Investor and Media section of our website. With that, I'll hand things over to Randy Teel. Randy?
Thanks, Jeff, and good morning to everyone. I want to begin by restating how committed we are to putting investment priority behind programs where new evidence points to the strongest chance of creating value, and to letting data guide how we allocate capital. If we follow through on that commitment, we think Arvinas can develop important medicines for patients and generate substantial long-term value for shareholders. We're now heading into a significant stretch of clinical milestones that we expect will further shape both each of our programs individually and the wider promise of our platform. Over the course of this call, I'll give an overview of our portfolio and our plans. Angela will add detail on our clinical programs, and Andrew will walk through our finances and how we approach capital allocation. I'll start with ARV-393, our oral BCL6 degrader, which is a strong illustration of a program with a solid scientific rationale for differentiation. BCL6 plays a central role in lymphoma biology, and we think our capacity to degrade this transcription factor — classically considered undruggable — could provide a differentiated way to treat B and T cell lymphomas. We see a chance for our BCL6 degrader to serve as a backbone of future treatment strategies, both as a monotherapy and combined with standards of care. That could include cutting back on, delaying, or sparing chemotherapy for patients. In the quarter, while we kept enrolling the monotherapy and combination cohorts of our Phase I trial, we submitted our initial monotherapy dose escalation data for presentation at the ASH conference in December; this marks the first of 2 data readouts for the program, with the second readout anticipated in mid-2027. The first disclosure will center on patients with T-cell lymphomas, where treatment options are limited. These data reinforce our view that ARV-393 is an active BCL6 degrader with the potential to be highly competitive as development continues. The data we share in 2027 will cover a larger share of patients dosed at levels expected to achieve efficacious exposures in B-cell lymphomas, stronger durability data, and initial data from the combination with glofitamab, the first of our planned combination cohorts. Next I'll turn to ARV-027, our first-in-class oral androgen receptor degrader aimed at the root cause of spinal bulbar muscular atrophy, or SBMA, which is also known as Kennedy's disease. This degrader targets the polyglutamine repeat androgen receptor, or polyQ-AR, present in patients with this genetically defined disease. SBMA is an X-linked disease in which polyQ-AR aggregates and gains a toxic function, causing progressive muscle weakness and functional decline. By eliminating the toxic buildup of polyQ-AR in muscle, we could potentially create the first-ever disease-modifying therapy for patients with this rare neuromuscular disease. The SBMA program is moving through multiple dose cohorts in its Phase I trial, and we plan to share initial data from the healthy volunteer cohorts in the first half of 2027. We also plan to start dosing patients with SBMA in the first half of 2027. If things go as planned, we think the Phase I data for this program will meaningfully reduce the risk for the program, and we'll start talking with health authorities about launching a registration-enabling trial. I'll move on now to ARV-6723, our first immuno-oncology degrader. Since it acts on the immune system in ways that go beyond what current IO therapies can do, we believe this first-in-class oral HPK1 degrader could turn into an important treatment for patients across 3 distinct paths: first, after a checkpoint inhibitor; second, together with a checkpoint inhibitor; and third, in indications where checkpoint inhibitors haven't demonstrated benefit. Given encouraging preclinical data as a monotherapy and in combinations, we started a Phase I trial in the third quarter. Dose escalation for monotherapy is underway, and we intend to begin dosing in combination with pembrolizumab during the first half of 2027. HPK1 is a protein that suppresses several parts of the cancer immunity cascade. And we think that by eliminating it, our degrader may be able to leverage the body's natural tumor immunity to fight cancer. We're eager to share initial data from this program in the second half of 2027. To complete the picture of our clinical progress, I'll now give a quick update on where things stand with our LRRK2 degrader, ARV-102. After receiving scientific advice from CHMP, we are now putting priority on starting a Phase Ib trial in the EU and the U.K. Next month, we intend to file clinical trial applications for a Phase Ib trial in patients who have progressive supranuclear palsy, or PSP. We're aiming to launch the trial in 2027; at the same time, we're consulting with Japanese health authorities to shape potential development in Japan as part of a long-term global clinical strategy. In the U.S., talks with the FDA continue regarding the ongoing clinical hold on our IND. Our goal now is to add U.S. sites to future trials once the Phase Ib trial in the EU and the U.K. is complete. Last month, we shared additional and novel biomarker findings from our Phase I trial, among them improvements on an objective and quantifiable measure of impaired eye movement linked to Parkinson's disease. All the evidence from our Phase I trial reinforces our confidence in what LRRK2 degradation could do to produce novel clinical breakthroughs for patients with devastating neurodegenerative diseases. What ties all of our programs together is the scientific premise that degrading the proteins responsible for disease lets us create transformational treatments that address unmet patient need; we are going after targets where removing the protein could change the treatment landscape and improve outcomes for patients. The progress we're making today is laying the foundation for the next wave of innovation at Arvinas and advancing our mission of delivering transformative medicines to patients. With that, I'll hand the call over to Angela. Angela?
Thank you, Randy. With several important pipeline milestones coming up, I want to show how the data from our preclinical work back up the differentiated nature of our science, help shape clinical development, and put our portfolio in a position to create value. To begin with ARV-393, our approach is to prove its potential both on its own and in combinations that might broaden the treatment choices available to lymphoma patients. In preclinical DLBCL models we have demonstrated potent single-agent activity, with enhanced effects, including complete tumor regressions, when it is paired with chemotherapy, biologics and investigational oral agents. Findings from R-CHOP and bispecific antibodies give us confidence in the combination strategy we are taking into the clinic. Our first Phase I disclosure will offer an early view of safety and tolerability, drug exposure, target engagement and antitumor activity. Those initial cohorts received doses lower than what we predict would be efficacious in preclinical DLBCL models. Even at these early dose levels, responses have been seen across NHL subtypes, including B and T-cell lymphomas. The disclosure will center on safety, PK and PD across all patients, plus preliminary efficacy from the early cohorts in T-cell lymphoma patients, a group whose treatment options remain limited. These data will inform dose selection and expansion plans. Our next update, anticipated in mid-2027, will cover more B-cell lymphoma patients dosed within the predicted efficacious range and followed longer, as well as first combination data with glofitamab. Now to our polyQ-AR degrader, ARV-027: our Phase I study is built to establish safety and tolerability and to determine whether the drug degrades the androgen receptor in skeletal muscle. Importantly, we are observing profound preclinical activity on muscle strength and endurance, 2 of the most fundamental manifestations of SBMA disease progression. In an aggressive mouse model of SBMA, ARV-027 induced polyQ-AR degradation in muscle, and the data showing rescue of muscle strength, endurance and survival excite us. Our therapeutic goal rests on internal data and literature evidence indicating that roughly 50% reduction of polyQ-AR in muscle improved strength and restored treadmill endurance in mouse models. We believe the upcoming multiple ascending dose data in healthy volunteers and SBMA patients will help establish whether ARV-027 produces the biologic effects required to support moving ARV-027 into a registrational trial; those results, alongside chronic toxicology data and regulatory interactions, will guide dose selection and the design of our SBMA clinical trial. We look forward to sharing initial data from our Phase I trial in the first half of 2027; now let's turn to ARV-6723, our first-in-class immuno-oncology asset and oral HPK1 degrader, which is now in a first-in-human Phase I trial. By removing HPK1, we aim to eliminate both its kinase and scaffolding functions, thereby releasing the brakes on innate and adaptive immunity more fully than kinase inhibition alone could. Specifically, our preclinical data demonstrate 3 compelling findings: first, robust single-agent antitumor activity across 7 checkpoint-resistant models, in which a clinical HPK1 inhibitor plus checkpoint therapy showed no activity. Second, complete tumor regressions with anti-PD-1 combination treatment. And third, there are intratumoral immune effects that go past T-cell activation, which include stronger interferon signaling and reshaping of the myeloid compartment. This wider remodeling of the tumor microenvironment could help shed light on why oral ARV-6723 shows differentiated activity and its potential to tackle tumors that don't respond well to current immunotherapies. Later this week, at the Society for Immunotherapy of Cancer Annual Meeting, we'll share additional preclinical data that reinforces this differentiation and backs our monotherapy and combination development strategy. Our Phase I monotherapy trial is going to assess safety, drug exposure, HPK1 degradation and biologic effects in tumors. Measures of immune activation, including NK and T cell activation, will let us translate the promising preclinical biology to patients and further guide clinical development. Moving on to ARV-102. A central goal of the program has been to build a comprehensive understanding of how LRRK2 degradation influences biologically relevant pathways tied to neurodegenerative disease. The Phase I data we presented at the MDS conference last month broadened our biomarker evaluation and gave us further insight into the molecule's pharmacology. The data showed ARV-102 achieved brain penetration and kept its potent and deep reduction of LRRK2 in the cerebrospinal fluid, or CSF, of patients with Parkinson's disease. ARV-102 also lowers endolysosomal and neuroinflammatory markers in the CSF that have been shown to be elevated in neurodegenerative diseases. Importantly, we presented novel data showing improvements in an objective measure of impaired eye movement associated with Parkinson's disease. The data showed that reductions in LRRK2 and CSF after treatment with ARV-102 correlate with changes in ocular motor function and in synaptic biomarkers tied to enhanced plasticity and cognitive resilience. These findings bolster our confidence in ARV-102's potential to advance treatment for neurologic diseases such as Parkinson's disease and progressive supranuclear palsy. As development continues, we're building on these results with biomarkers and functional measures to link target degradation with downstream biologic effects and potential patient benefit. In closing, we're excited about the potential of each of these programs, with key data insights offering evidence to guide their advancement. We look forward to sharing our progress over the next several quarters. With that, I'll hand the call over to Andrew to review our financial results.
Thanks, Angela, and good morning, everyone. I'm glad to take you through the key financial points from Q3 2026. Just to note, the release we put out this morning includes full financial details for the third quarter. We're approaching a stretch with significant clinical readouts ahead, backed by an innovative portfolio, well-defined milestones, and the financial capacity to produce impactful clinical data that will guide our choices on the main programs. When the third quarter ended, our balance sheet showed $558.9 million in cash, cash equivalents, restricted cash, and marketable securities, compared with $685.4 million at the close of 2025. Thanks to a strong balance sheet and the cash we expect to generate through the latter part of 2028, we have a solid foundation for continuing work on our promising oncology and neurology programs. I'm pleased to report that in the third quarter we recorded our first royalty payment under the license agreement with Rigel. That $0.5 million royalty shows up in the revenue section of our P&L, while the corresponding Yale royalty is recorded on the cost of license revenue line. For the third quarter, general and administrative expenses were $12.6 million, versus $21 million in the same period of 2025. The drop of $8.4 million came mainly from lower personnel and infrastructure-related costs, which fell $4.2 million, reduced spending on developing our commercial operations of $1.8 million, and professional fees that were $1.5 million lower. Research and development expenses totaled $46.9 million in the third quarter, versus $64.7 million in the same period of 2025. That $17.8 million decline was driven largely by our program expenses coming down by $7 million, non-program-specific expenses decreasing by $3.5 million, and compensation and related personnel expenses falling $6.5 million, which are not allocated by program. Non-GAAP R&D expenses declined $12.6 million from the same period last year, a reduction of 22%. Non-GAAP G&A came in $5.4 million lower, a 37% drop from the same period a year earlier. Quarterly non-GAAP expenses totaled $53.5 million, versus $71.5 million in the prior-year period. That 25% year-over-year decrease in expenses reflects lower spending throughout the organization, including reduced development spend and cuts in G&A. Our spending this quarter is a solid picture of what we expect over the coming few quarters as we keep advancing our early-stage pipeline. All year long we've stayed disciplined about portfolio decisions and capital allocation, and with cash runway extending into the second half of 2028, we can fund operations through several key data milestones. We tell investors plainly: capital will be deployed with care, we'll communicate openly, and the evidence will decide where our investments go. If we follow through on that promise, we'll be strongly placed to develop meaningful medicines for patients and to generate substantial long-term value for shareholders. In our view, that creates a solid opportunity for value creation over time, as the next wave of clinical results comes in and reveals where protein degradation can offer genuine benefits to patients. That said, I'll turn it over to Randy for his closing remarks. Randy?
Thanks, Andrew. Looking forward, several significant clinical milestones are coming up over the next few months. The first is the initial of 2 data disclosures for our BCL6 degrader, scheduled for December, with a second disclosure to follow in mid-2027. We're also on track to share Phase I data for our polyQ-AR degrader during the first half of 2027, along with initial data from our HPK1 degrader in the second half of 2027. In addition, we're working tirelessly to secure approval to begin a Phase Ib clinical trial of our LRRK2 degrader in patients with PSP in 2027. I'll close with what I consider most important. Arvinas has already achieved a major win, going from a scientific promise to the first ever FDA-approved PROTAC degrader. What lies ahead is demonstrating that this was only the start of what we expect will be multiple successes in delivering important new options to patients in need.
Thanks, Randy. Operator, will you please open the queue?
Great to hear from you folks. Nice progress throughout the pipeline. I have two quick questions, if that's alright. The first concerns the clinical hold on 102. Could you just remind us where things stand on getting that resolved with the FDA? What steps remain to be done? And then perhaps a quick one for Andrew. Would you remind us of the parameters for the Yale royalty, both regarding the percentage, and whether it applies to all of the programs that follow?
Thanks, Ted, and great to hear from you too. Yes; so regarding 102, as we mentioned today, the plan is to proceed with the Phase Ib CTA process in Europe. As for the U.S., we continue to have conversations with the FDA aimed at getting off that clinical hold. Right now, investors should assume that the Phase Ib will start without U.S. patients; but that doesn't mean that later in the development plan, we couldn't bring the U.S. back in. There's only so much I can say while conversations with the FDA are ongoing, but that's where we stand at present. We're confident that we can carry out that Phase Ib in Europe as we complete the CTA process, should it succeed; but that's how we'll move forward for now. Andrew, on the Yale license agreement.
Yes, thank you for asking. So, regarding the Yale agreement, there is a royalty involved. It's a fairly modest royalty—roughly 1% on royalty revenue. That will continue going forward. It doesn't cover every one of our programs. I don't think we've revealed which programs fall under the Yale royalty and which don't. I believe we'll share that as we move nearer to commercialization for the remaining programs, since the agreement we have with Yale is complicated. And then for milestones and upfront payments, the figure is somewhat higher. You could likely look back at what we paid Rigel. I won't reveal that figure, but it's somewhat higher—still low single digit. Does that answer your question, Ted?
Great, guys.
Congratulations on the progress. I have two questions. First, for your polyQ-AR degrader program, are you aiming for roughly a 50% reduction in AR among healthy volunteers? And in the SBMA cohort that you'll be dosing in the first half of next year, which endpoints will be evaluated?
Yes. Thanks for the question, Jeet. I'll begin and then hand it over to Angela. Just to review where we are, we're dosing healthy volunteers at present; ideally we'll reach SBMA patients in the first half of next year. The short answer to your question about 50% degradation is yes, but I'll let Angela dive into the details on that.
Yes, so our aim is a 50% decrease in polyQ-AR. What we're really trying to do is preserve a degree of androgen tone while demonstrating that we can cut the androgen receptor by 50%, and in our preclinical models, as well as in what's been published, that level of reduction produced recovery of really key endpoints, including muscle function and endurance in those models. So that, I hope, clarifies the reasoning. Thanks for asking.
And if you wouldn't mind, just one quick follow-up. Regarding ARV-102, how closely do gains in ocular motor function line up with overall disease progression, or with improvement in motor symptoms, in Parkinson's?
Great question. So the endpoint we measured is a novel one — the amplitude of psychotic hypometria. Based on published literature, it does show concordance with the UPDRS, though how well that concordance holds and translates into clinically meaningful improvement is still to be proven. With that said, our data encourage us, showing changes in 2 different synaptic endpoints — one being CSF improvement in meaningful biomarkers such as neuronal pentraxin-2, which is linked to cognitive resilience, and also, again, the psychotic eye movement, which measures basal ganglia synaptic activity.
The other point I want to make, Jeet, is this — and I believe this is — you raised the question about 027 and 102, and I think what's similar in both cases is that it's really important to do work exploring potential biomarkers for use in the trials or with patients over time. Both of these are rare diseases, and both of their first trials for approval will likely be rating scale-based trials. But that doesn't mean we can't, at the same time, be exploring biomarkers that may correlate over time; that holds for both 102 and 027. And regarding 027, the most important biomarker is the degradation of polyQ-AR itself, which in this case is actually what's driving the disease. So this biomarker will matter over time, and we believe there are opportunities to pursue them across both programs.
I wanted to ask whether you might give us a brief update on where things stand regarding partnering prospects for ARV-806, the KRAS G12D degrader?
Yes. Thanks for that question, Yigal. As we announced, that program is going to advance only if there is a partner. So once a partner is identified, we will aim to give an update on it at that point. That program — we announced this earlier in the year — will have some data coming next month; this month, at a conference, so watch for that too. But once more, that program will move forward solely with a partner. So we will keep giving guidance on the programs that we are continuing to advance in Phase I as wholly-owned programs.
All right. Now turning to ASH — you're sitting in what you called sort of below. Could you give us a bit more color on what we should anticipate on the efficacy side? Are you observing efficacy at a lower dose than you'd originally expected? And what sort of clues from that early signal would give you confidence to go higher?
Yeah. Thanks for that question too. Right. So the first disclosure for the 393 program — the BCL6 degrader — comes at the end of the year, as you said. Then we'll have another one in the middle of next year. So we truly view it as a 2-parter. What matters most in a first data disclosure is demonstrating that the preclinical work translates into the clinic. So it will always lead with things like safety, and PK and PD tolerability will be really important — particularly for a program like this where, over time, the development plan will include both monotherapy and combinations; so as we've said previously, we need to be sure we're seeing good PK. We've also disclosed that we started dosing at fairly low doses, well below the exposures we'd expect to be efficacious. We want to see solid degradation of BCL6; this is a transcription factor that gets rapidly resynthesized, so you need to observe robust BCL6 degradation. And on efficacy, we're going to center the first disclosure on T-cell patients. If you're a second-line plus patient with nTFHL right now, you're getting roughly a 35% to 45% response rate with drugs currently on the market, even though there are no specifically approved therapies for second-line T-cell patients like this — which is actually a good reminder of the unmet need in this space. So with marketed therapies achieving roughly 35% to 45% in a first dose escalation study at low doses like the ones we're at now, we and the investigators would be pretty excited by anything above really a 30% response rate. Certainly we'd look for that to rise as we dose higher. But in an early setting like this, with most patients dosed below the levels where we expected efficacy, that would be a reasonable bar to set. I hope that's helpful, Yigal.
Congratulations on the progress. I want to build on what Yigal asked about ASH. Since you're mainly going to report efficacy in T-cell patients, while your rival in the degradation space concentrates heavily on B-cell patients, I was wondering how we should view read-through between those indications, and how we should consider your molecule's potency compared with the competitor's? Also, how should we think about expanding past T-cells into B-cell indications over the next year?
Yes. Excellent question, Jonathan. I appreciate it. As we've mentioned, our disclosure in the middle of next year will center on B-cell patients; we're including them from an efficacy standpoint. The rationale there is quite straightforward, correct? The modeling we reference when discussing dosing beneath exposures projected to be efficacious is actually carried out in B-cell, LBCL models. So that's where we think that if you take the patients we currently have and you trim at the end by how many patients are dosed at a level where you'd anticipate efficacy across various indications with response-evaluable capabilities or factors, that count becomes quite small. And we want to be sure the data we present is informative for investigators and investors. That's the reason we concentrated the first disclosure on T-cell, and we'll hold off on the B-cell disclosure for full B-cell disclosure once we have additional patients at higher doses, plus the ability to demonstrate durability and also to demonstrate some combinability with glofi while that trial is ongoing, and we'll have more patients to share by the middle of next year. Regarding translatability, we have observed responses in both B-cell and T-cell patients at lower doses. We stated that even a year ago. So I believe there could be some transferability, but it will be more informative to hold off until we present the data in B-cell patients, where you can truly gain a good sense with more patients, higher doses, more durability.
Great; and if I could just squeeze in one more thing about LRRK2. I was hoping you might expand a bit, over the medium to longer term, on how this Phase Ib in the EU and U.K. will translate into possible registrational paradigms. What's your latest thinking on the timeline for getting into registration?
Yes. Good question. Thanks. So where our thinking stands now — and Jonathan, you'll recall that roughly a year ago we had discussed the possibility of 2 trials, a Phase Ib in the U.S. and a registrational trial that would be more global. What that is now folding into is the Phase Ib trial first, which, as we mentioned, will be in Europe, and then we'll look to move to registration after that. So it's a little early to provide too much in the way of specifics for that trial, but we'll want to be dosing patients with PSP now over a longer time period. I'll remind you that in healthy volunteers and PD patients we had dosed only for 28 days. So this would be longer, giving enough time to get a good sense of safety, PK/PD as always, and perhaps also some efficacy-oriented endpoints, where the goal of that Phase Ib trial is to gain the confidence to move into a registrational trial that's larger and comes later on. So that's how it plays out now. Going back to the remarks we made on the call, there could be an opportunity at that point to make it a development program that's more global, potentially including Japan and the U.S; and other geographies. But we'll need to get through the Phase Ib trial first; and as we said on the call, we'll look to start that trial in 2027 after getting through the CTA process in the EU and the U.K.
Going back to 393 once more. You gave us the bars for the early data at ASH, and that's a big help; but when we look at the data mid next year, what will you be watching for there, both with the potentially higher doses and with the glofi combo? And could you get onto a registrational path quickly after those data?
Thanks for those questions, Nick. Let me take the second one first. Yes, I believe that's possible when it comes to T-cell patients, where, as we've discussed, the unmet need is pretty significant; as for how we think about what good looks like, which I know is really what you're asking, this program was really our first undruggable, right? So going into BCL6 after the early success with AR and ER was a chance to demonstrate what a degrader can do in a space where no degraders had gone before — sorry, where no BCL6 programs had reached the clinic. The inhibitors haven't gotten there; so the question of what good looks like for BCL6 is beginning to be answered by our competitors in the space already, which is great news, because it shows that the target we chose a while ago does have some efficacy. So as for what good actually looks like, that bar is going to be set, right? It's a bit early to discuss it now. But at present, patients on a monotherapy BCL6 degrader — and you've seen some other players with response rates above 50% — while we don't view this as a winner-take-all setting, we certainly see it as an important setting in which to show we can be competitive. I'll say something specific about the glofi combo. In the glofi combo we're running, glofi is a quite active agent; so the aim of the glofi combo will really center on showing combinability. Of course, efficacy can't be worse than glofi already has, but we would expect good responses from glofi already. And in a small dose escalation trial, that isn't the place to look for better performance than glofi; so really, the outcome we're after there is combinability, and of course, continued translation of safety, PK, PD.
Building on Randy's comments, the reason the B-cell combination approach is so compelling also comes down to the increased CD20 expression we observe, which should translate into better combinability with rituximab—so R-CHOP—and with bispecifics such as glofitamab as well. We're genuinely enthusiastic about nailing down the depth and durability of B-cell responses.
Just a few quick follow-ups. Is the choice to move into SBMA patients with ARV-027 going to depend on reaching that muscle degradation threshold you mentioned earlier in healthy volunteers? And then regarding the PSP Phase Ib study with ARV-102, I'm just trying to get a handle on it — is the launch in the EU and U.K. mainly about differing requirements for chronic toxicology data for this asset? Is that really the key factor behind being able to begin that study there instead of in the U.S.? Any input on that would be useful.
Thanks, Etzer. On the first one about SBMA patients — no. What I take your question to mean is whether the healthy volunteer studies will act as a gate before we begin SBMA patients, whether we need to observe some particular level of degradation. The answer really is no. The multiple dose part of the healthy volunteer study is truly meant to identify a dose, one single dose, that we can then carry forward into the Phase I in patients with SBMA. It's a rare disease. So finding a large number of patients to use in a Phase I study isn't super easy, particularly since, as we've said, that Phase I study will be pretty derisking and ought to supply the evidence from a biomarker standpoint to move into a registrational study. We would love to be preserving patients so they can move into a registrational study before too long. Anything else on that, Angela, before we move on to the 102 that you think should be added?
I believe you've got that right, Randy. And I think it makes a lot of sense to use one site for conducting a Phase I trial in healthy volunteers and then transitioning to SBMA, given how experienced that single site is—the one we're using for this study—when it comes to collecting biomarkers.
Thanks. On the ARV-102 question and the various regulatory discussions, it's genuinely difficult to say much about those conversations while they're ongoing. But what you should take away, Etzer, is that every one of those discussions involves multiple factors; and since we're telling you we'll proceed through the CTA process with Europe, you can take it that we've received scientific feedback that we believe gives us a route forward into those CTA conversations and to launching a trial within the next year, while in the U.S. it appears things will take somewhat longer. We want to be sure we're advancing the program toward proof of concept as quickly as possible. We believe that matters a great deal for demonstrating the program's value. We're confident we can accomplish that through studies in Europe; so that's where our focus will be.
This is < > on for Tazeen. Perhaps a question about ARV-027. Maybe just what are you guys looking for regarding safety and tolerability in the healthy volunteer cohort as you work toward that roughly 50% degradation level? And then longer term, if you're able to hit that level in SBMA patients, just curious how you're thinking about the — how long it would take to see translation into functional benefit. If there's any read-through that you guys have from your mouse work that informs that timing?
Thanks for the question. Angela, please dive in.
Yes. So ARV-027 isn’t really different from any other molecule undergoing safety testing. In that Phase I dose escalation, we’ll be examining every aspect of safety and tolerability. Reaching that 50% mark stems from our preclinical data, where we did achieve a 50% reduction in polyQ-AR; removing that disease driver restored strength, endurance, and survival in that model, and other models have shown the same effect as well. So translating time into clinical benefit is very difficult. But what’s exciting is that as we move into the clinic, we’ll be looking at muscle integrity. We’re taking a close look at natural history data and are grateful to patients as well as NITO for providing us with their data so we can take a closer look at clinical endpoints that we’ll be looking to translate in our registrational SBMA trial. So I’ll just — I think that covers it.
One more point to add, since I don't believe we mentioned it during the call or reminded people about it. ARV-027 degrades wild-type and polyQ-AR about equally well. In SBMA patients, however, only the mutant polyQ-AR form is present—this is an X-linked disease in which patients carry just one form—and that's precisely why we believe the studies we're running in healthy volunteers first ought to be highly predictive of what we'll observe in SBMA patients: whether we can make 027 orally bioavailable, get it into muscle, and degrade the target protein in the place where degradation is needed, and then wild-type degradation should predict polyQ degradation, which, as we've noted, is a fairly clear marker given that this protein is actually the one driving disease.
Thanks for the update. Perhaps a follow-up regarding the 393 ASH update. How many T-cell lymphoma patients should we be expecting? Are there sufficient patients to potentially evaluate dose response? And what about durability, given that many agents in this space have demonstrated rather modest PFS?
Yes. Thank you, Lee. So regarding T-cell patients, when we look at efficacy, I believe mid-teens or so, with the same caveat that obviously the patients dosed at the highest levels, which is where you would be more likely to observe efficacy, will have the shortest follow-up simply by definition in a dose escalation trial. Thus the durability information in this update will be fairly limited, and you should expect to see more next summer as we bring in both T-cell and B-cell patients. We will show some. But to my point, the patients dosed at the highest levels will be the ones by definition with the shortest follow-up, I think mid-teens or so for T-cell patients.
I've got another question about your HPK1 degrader program. I'm just wondering: how much proof-of-concept data are you planning to produce before you decide on the next steps? And how do next-gen IO agents such as PD-1 and VEGF shape your thinking about where you might fit in?
Yes. Thanks for asking, Lee. I'd say the short answer is: not much. What I mean is, we've started that Phase I trial of the HPK1 degrader, and we believe this program could have applicability well beyond what PD-1 therapies have achieved. While PD-1 therapies have succeeded well at countering T-cell exhaustion, we believe HPK1 acts as a brake at several stages of the immune cascade, so breaking it down ought to deliver an advantage. That study is still running, with initial results anticipated in the latter half of next year, and it will enroll only patients who have already received checkpoint inhibitors. Other agents have not fared well in that population, yet we believe HPK1 can show a difference there. The evidence supporting that move actually stems from our preclinical research, in which we got past roughly seven models resistant to immune checkpoint inhibitors and demonstrated superior results compared with both PD-1 therapies and an earlier HPK1 inhibitor. That data will be shown in greater detail this week at SITC, should you check our poster there. Lee, I left unanswered your question regarding next generations, PD-1, VEGF and the like. Well, an oral new approach to immune — pardon me, to an IO therapy, in our view, could prove quite broadly applicable no matter what those other next generations happen to be doing. It isn't really — I don't truly see it as competition in that space. This represents a separate target whose bodily functions differ, giving us new ways to intervene. As stated, we plan to begin pairing it with pembro during the first half of next year—yet do not take that as the sole combo available to us.
On the preclinical side, data around additional combinations like the ones you brought up will be shared before long, along with other activities we observe in the tumor microenvironment that, in our view, look highly promising for ARV-6723 as an oral agent.
Alex here, filling in for Kripa. I’ve got a question about capital allocation. With the runway we have now extending into the second half of 2028, which clinical milestones are fully funded? And which trials and expansion cohorts are included in that?
Yeah. Thanks for asking. Look, first of all, we are fully funded on BCL6 through next year, right? So the ascending monotherapy and the combination are both funded. We’ve also put funding toward some of the expansions where we’ll begin exploring combinations. I won’t go into detail there, because I don’t believe we’ve laid out our complete development plan for that yet, but we intend to expand and test combinations beginning next year across a number of therapies; all of those are funded. We have funded SBMA through the period covered by our guidance. Obviously, the trial runs somewhat beyond the point where our cash guidance reaches. So we’ll need to clean that up at some point down the road. But I think since those are the major programs, that’s probably where I’ll leave it with the guidance. We take great care to ensure we have cash through to the next key readouts, right? And with cash into the second half of 2028 and all of those funded, we believe we’re there. So hopefully, that helps.
Yes, that's great.
This is Jacob, filling in for Derek. We just have one question about LRRK2. Should we expect ocular motor and biomarker data comparable to what you've generated in PD to also come out of the PSP Ib study? And if that's the case, how should we think about that relative to either comps or natural history data?
That's a really good question, Jacob. I'll let Angela speak to the specifics of the ocular motor work, which is really interesting.
Right, and with PSP in particular, the onset of that gaze palsy happens quite differently and much earlier. So what we're doing is shifting our digital biomarkers back toward endpoints we consider more meaningful in this disease—movement and falls. Those are the endpoints we'll be using. Eye tracking is certainly one thing that will be examined, but we're also looking at markers of endolysosomal function and inflammatory markers, and importantly, translating the pathologic tau reductions we saw, which are the main hallmark driving PSP. So we're eager to examine those endpoints, along with synaptic markers that are key to PSP progression, including neuronal health markers such as neurofilament light chain. That gives you a sense of some of the additional markers we're evaluating in that PSP trial compared with what we evaluated in PD.
Much appreciated, operator. I want to thank all of you for being with us this morning. A special thanks as well to the patients, the physicians, and every one of our team members at Arvinas who make this work possible. We're eager to bring updates to the community over the months ahead. Many thanks to everyone.
Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Arvinas, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Arvinas, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.